2021-01-17| M&A

Thermo Fischer Snags Novasep’s Low-Cost CMO for $879 Million

by Sangeeta Chakraborty
Share To

On January 15th, Thermo Fisher Scientific announced the acquisition of Henogen, Novasep’s viral-vector manufacturing division in Belgium, for about $879 million in cash. It will be part of Thermo Fisher’s pharma services business within the laboratory products and services segment.

Viral-vectors such as adeno-associated virus (AAV) vectors are used in gene and cell therapies to deliver RNA and DNA into cells. Biopharma giant AstraZeneca has been using an adenovirus vector for its COVID-19 vaccine candidate, and Novasep, last November, had signed a multi-year deal with the company to support its large-scale manufacturing of the adenovirus vector.


Henogen – Low-Cost CMO

Henogen, Novasep’s production facility across two locations in Belgium, is a global provider of low-cost manufacturing services for a range of products and processes, including active molecules, vaccines, and therapies to biotech and pharma companies. The company has more than 75,000 square feet of clinical and commercial production space with about 400 employees. The business’s estimated 2020 revenue was approximately $97 million.

“Novasep’s viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally,” said Michel Lagarde, Executive Vice President of Thermo Fisher.

“The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America,” Lagarde said. “In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors. The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe.”

Michel Spagnol, President and Chief Executive Officer, Novasep, said, “Thermo Fisher is an outstanding partner for our viral vector business and its future development. Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher. Our talented employees will bring deep expertise to an organization that shares our commitment to providing ground-breaking new medicines to patients.”

The acquisition of Henogen marks Thermo Fisher’s second big purchase of a viral-vector business after it acquired Brammer Bio in 2019 for $1.7 B. Riding high on the success of its COVID-19 test kit over the last year, Thermo Fisher has made great strides in expanding its manufacturing capabilities to 20 million per week to accommodate the rising need.

By Sangeeta Chakraborty, Ph.D.

Related Article: Sanofi Looks to Bolster Immunology Pipeline By Acquiring Kymab for $1.5 Billion



© All rights reserved. Collaborate with us:
Related Post
GeneOnline’s Weekly News Highlights: Oct 16-Oct 20
GeneOnline’s Weekly News Highlights: Sept 4-Sept 8
GeneOnline’s Weekly News Highlights: July 3-7
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top